These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 20446233

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Vernakalant hydrochloride for the treatment of atrial fibrillation.
    Kozlowski D, Budrejko S, Lip GY, Mikhailidis DP, Rysz J, Raczak G, Banach M.
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1929-37. PubMed ID: 19938903
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Vernakalant in the management of atrial fibrillation.
    Cheng JW.
    Ann Pharmacother; 2008 Apr; 42(4):533-42. PubMed ID: 18334607
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The pharmaceutical pipeline for atrial fibrillation.
    Santangeli P, Di Biase L, Pelargonio G, Burkhardt JD, Natale A.
    Ann Med; 2011 Feb; 43(1):13-32. PubMed ID: 21166558
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for the potential treatment of atrial fibrillation.
    Billman GE.
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1048-58. PubMed ID: 20730700
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.
    Duggan ST, Scott LJ.
    Drugs; 2011 Jan 22; 71(2):237-52. PubMed ID: 21275448
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A new antiarrhythmic drug in the treatment of recent-onset atrial fibrillation: vernakalant.
    Vizzardi E, Salghetti F, Bonadei I, Gelsomino S, Lorusso R, D'Aloia A, Curnis A.
    Cardiovasc Ther; 2013 Oct 22; 31(5):e55-62. PubMed ID: 23398692
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Novel agents for the acute conversion of atrial fibrillation: focus on vernakalant.
    Cialdella P, Pedicino D, Santangeli P.
    Recent Pat Cardiovasc Drug Discov; 2011 Jan 22; 6(1):1-8. PubMed ID: 21235460
    [Abstract] [Full Text] [Related]

  • 18. Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?
    Ehrlich JR, Nattel S.
    Curr Opin Cardiol; 2009 Jan 22; 24(1):50-5. PubMed ID: 19077816
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Spotlight on intravenous vernakalant in recent-onset atrial fibrillation.
    Duggan ST, Scott LJ.
    Drugs Aging; 2011 Jun 01; 28(6):501-4. PubMed ID: 21639409
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.